PropertyValue
?:definition
  • A proprietary preparation of autologous T lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a second-generation chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T cells C-CAR011 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Check for \'https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C141050\' active clinical trials using this agent. (\'http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C141050\' NCI Thesaurus)
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
expand all